Skip to content

Sacituzumab govitecan

Trodelvy (sacituzumab govitecan) is an antibody pharmaceutical. Sacituzumab govitecan was first approved as Trodelvy on 2020-04-22. It is used to treat triple negative breast neoplasms in the USA. The pharmaceutical is active against tumor-associated calcium signal transducer 2.
Trade Name Trodelvy
Common Name Sacituzumab govitecan
Indication triple negative breast neoplasms
Drug Class Monoclonal antibodies: humanized, tumors as target; antineoplastics (camptothecine derivatives)
Sacituzumab govitecan
Get full access now